Rallybio Corporation

US$15.75As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:RLYBHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (33.56%)
Div yield —
ROE 34.52%
Biotechnology
Beta (5Y) (0.77)
PE TTM 3.385
TSR TTM 182.30%
Mkt cap US$84.80M
ROIC (17.62%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$16
4.45%
117.39%
Hold 7|5|1|6|4
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.34
0.34
0.37
0.38
(0.18%)
2.96%
17.49%
22.69%
Revenue$M
4.316
4.335
4.338
4.336
7.13%
7.47%
6.42%
6.13%
Peers (US$84.80M)
Cap (US$)
PE
84.17M
—
Capital
TTM
5Y
10Y
Leveragex
0.668
(0.112)
(0.102)
EBIT/Intx
4.366
0.070
0.073
Own earn%
25.04
32.69
65.05
Sh yield%
51.59
13.09
13.06
Owners
Insiders/Inst%
3.86
74.80
Short interest%
1.65
SBC / revenue%
1.17
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
7
Op margin range%
0–2
$1 testx
—
Incr. ROIC%
0